NA
INDV icon

Navellier & Associates’s Indivior Pharmaceuticals INDV Stock Holding History

Navellier & Associates’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.13M Buy
173,860
+39,752
+30% +$1.44M 0.57% 37
2026
Q1 		$4.09M Buy
134,108
+19,204
+17% +$634K 0.43% 56
2025
Q4 		$4.12M Buy
+114,904
New +$3.51M 0.46% 52

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Navellier & Associates's INDV Position: Q2 2026 in Review

Navellier & Associates increased its Indivior Pharmaceuticals (INDV) stake by 30% in Q2 2026, buying an estimated $1.44M and bringing the position to 173,860 shares worth $7.13M. The position accounts for 0.57% of the portfolio, ranked #37.

Navellier & Associates first reported a position in INDV in Q4 2025 and has held it in 3 quarters since. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Navellier & Associates held 173,860 shares of Indivior Pharmaceuticals worth $7.13M as of Q2 2026.
  • Navellier & Associates bought 39,752 Indivior Pharmaceuticals shares in Q2 2026, an estimated $1.44M.
  • Indivior Pharmaceuticals made up 0.57% of Navellier & Associates's portfolio in Q2 2026, its #37 holding.
  • Navellier & Associates first reported a position in Indivior Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Navellier & Associates's 13F filing for Q2 2026, filed 4 Aug 2026.